1. DB DB United Kingdom says:

    Here are some studies on prostate cancer and XMRV:

    'Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant' Urisman A et al. (31 March 2006
    'Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer' Fischer F (29 September 2008)
    'No evidence of XMRV in Irish prostate cancer patients with the R462Q mutation' D'Arcy F et al. (March 2008)
    'Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients' Hohn O et al. (16 October 2009)
    'XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors' Schlaberg R et al. (8 September 2009)
    'Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in dutch prostate cancer patients.' Verhaegh GW et al. (28 September 2010)
    'Detection of Xenotropic Murine Leukemia Virus–Related Virus in Normal and Tumor Tissue of Patients from the Southern United States with Prostate Cancer Is Dependent on Specific Polymerase Chain Reaction Conditions' Danielson et al. (J Infect Dis., 11 October 2010)
    'XMRV: A New Virus in Prostate Cancer?' Aloia er al. (American Association for Cancer Research, 21 October 2010)

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.